Logo image of SHPH

SHUTTLE PHARMACEUTICALS HOLD (SHPH) Stock Fundamental Analysis

NASDAQ:SHPH - Nasdaq - US8256933024 - Common Stock - Currency: USD

3.91  -0.06 (-1.51%)

After market: 3.88 -0.03 (-0.77%)

Fundamental Rating

0

Taking everything into account, SHPH scores 0 out of 10 in our fundamental rating. SHPH was compared to 555 industry peers in the Biotechnology industry. Both the profitability and financial health of SHPH have multiple concerns. SHPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SHPH has reported negative net income.
In the past year SHPH has reported a negative cash flow from operations.
In the past 5 years SHPH always reported negative net income.
In the past 5 years SHPH always reported negative operating cash flow.
SHPH Yearly Net Income VS EBIT VS OCF VS FCFSHPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

The Return On Assets of SHPH (-364.87%) is worse than 94.77% of its industry peers.
With a Return On Equity value of -1289.63%, SHPH is not doing good in the industry: 82.88% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -364.87%
ROE -1289.63%
ROIC N/A
ROA(3y)-170.32%
ROA(5y)-174.67%
ROE(3y)-496.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SHPH Yearly ROA, ROE, ROICSHPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

SHPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SHPH Yearly Profit, Operating, Gross MarginsSHPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

SHPH has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, SHPH has a worse debt to assets ratio.
SHPH Yearly Shares OutstandingSHPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2020 2021 2022 2023 2024 50K 100K 150K 200K
SHPH Yearly Total Debt VS Total AssetsSHPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -14.79, we must say that SHPH is in the distress zone and has some risk of bankruptcy.
SHPH's Altman-Z score of -14.79 is on the low side compared to the rest of the industry. SHPH is outperformed by 80.36% of its industry peers.
A Debt/Equity ratio of 1.23 is on the high side and indicates that SHPH has dependencies on debt financing.
With a Debt to Equity ratio value of 1.23, SHPH is not doing good in the industry: 79.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Altman-Z -14.79
ROIC/WACCN/A
WACCN/A
SHPH Yearly LT Debt VS Equity VS FCFSHPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 1.44 indicates that SHPH should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.44, SHPH is doing worse than 81.80% of the companies in the same industry.
SHPH has a Quick Ratio of 1.44. This is a normal value and indicates that SHPH is financially healthy and should not expect problems in meeting its short term obligations.
SHPH has a worse Quick ratio (1.44) than 81.26% of its industry peers.
Industry RankSector Rank
Current Ratio 1.44
Quick Ratio 1.44
SHPH Yearly Current Assets VS Current LiabilitesSHPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.87% over the past year.
EPS 1Y (TTM)9.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SHPH. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SHPH Price Earnings VS Forward Price EarningsSHPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SHPH Per share dataSHPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SHPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SHUTTLE PHARMACEUTICALS HOLD

NASDAQ:SHPH (7/3/2025, 8:09:05 PM)

After market: 3.88 -0.03 (-0.77%)

3.91

-0.06 (-1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2022-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners2.3%
Inst Owner Change-36.95%
Ins Owners12.93%
Ins Owner Change0%
Market Cap42.93M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 60.54
P/tB 60.54
EV/EBITDA N/A
EPS(TTM)-79.65
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -364.87%
ROE -1289.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.32%
ROA(5y)-174.67%
ROE(3y)-496.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.44
Quick Ratio 1.44
Altman-Z -14.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.03%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.28%
OCF growth 3YN/A
OCF growth 5YN/A